ライフサイエンスコーパス: clinical stage

1 t (P = 0.007 in early and P = 0.0048 in late clinical stages).

2 er at the target site, are mostly at the pre-clinical stage.

3 036 was associated with N classification and clinical stage.

4 for these patients based on the pretreatment clinical stage.

5 ere positively correlated with pN status and clinical stage.

6 antigen level, Gleason grade at biopsy, and clinical stage.

7 tion drug candidates from the preclinical to clinical stage.

8 disease progression shown to correlate with clinical stage.

9 y, the infection is chronic, with subsequent clinical stages.

10 ich side effect information for drugs at all clinical stages.

11 is, on the basis of the subclassification in clinical stages.

12 t differed considerably among treatments and clinical stages.

13 ne of these products has yet progressed into clinical stages.

14 from mechanical tissue substrates among ARVC clinical stages.

15 World Health Organization classification and clinical staging.

16 gible for sphincter-sparing surgery based on clinical staging.

17 phocytes of OSCC patients with early or late clinical staging.

18 men included in the study, 363 (98%) had WHO clinical stage 1 disease, 364 (99%) had high functional

19 tre, prospective, cohort study patients with clinical stage 1 endometrial cancer of all histologies a

20 ll tolerated when given to children with WHO clinical stage 1 or 2 HIV disease along with high antire

21 In analysis of only WHO clinical stage 1 or 2 HIV-infected children (n = 68), si

22 rs with normal motor scores through to early clinical stage 2 disease.

23 on activity of most other HAP, including the clinical stage 2-nitroimidazole mustard TH-302, dinitrob

24 (> or = IIB), sensitivity was poor for FIGO clinical staging (29%), CT (42%), and MRI (53%); specifi

25 es were eligible if they reported death, WHO clinical stage 3 or 4 events, admittance to hospital, se

26 hypospadias, and micropenis consistent with clinical stage 3 partial androgen insensitivity.

27 Among the index patients, 76% had clinical stage 3, 4, or 5 FEVR and 24% had stage 1 or 2

28 The crude incidence of histological or clinical stage 3-4 acute intestinal GvHD until day 100 o

29 Histologic and clinical stage 3-4 intestinal GvHD after 12 months occur

30 CD4 cell counts or World Health Organization clinical stage 3/4 disease.

31 endpoint of death, World Health Organization clinical stage 4 disease, or CD4(+) counts of <200/mm(3)

32 s (54 died, 45 had World Health Organization clinical stage 4 events, and 49 had poor immunological r

33 d new or recurrent World Health Organization clinical stage 4 events, or had poor immunological respo

34 and MRI (53%); specificity was 99% for FIGO clinical staging, 82% for CT, and 74% for MRI; and negat

35 d negative predictive value was 84% for FIGO clinical staging, 84% for CT, and 85% for MRI.

36 rom LRR at 5 years ranged from 86% to 97% by clinical stage, 86% to 97% by pathologic stage, and 71%

37 In addition to clinical staging, a number of biomarkers predicting over

38 We compared the distribution of grade and clinical stage across the pre-PSA and PSA screening eras

39 c physiological and HRCT variables to form a clinical staging algorithm predictive of mortality in a

40 vention strategies, guided by evidence-based clinical staging algorithms.

41 was significantly higher with more advanced clinical stage (Alzheimer's disease > mild cognitive imp

42 -to-lead and lead optimization campaigns and clinical stage and approved drugs, reflecting their incr

43 arian cancer patients present at an advanced clinical stage and develop resistance to standard of car

44 d remained significant after controlling for clinical stage and Gleason grade and was stronger for pr

45 After adjusting for clinical stage and grade (likely intermediates of the re

46 sidered together with gains in 8q as well as clinical stage and histologic grade of malignancy.

47 omarker of GI GVHD that can be combined with clinical stage and histologic grade to improve risk stra

48 More advanced clinical stage and later year of diagnosis were the only

49 .01) in Cox multivariate analysis, including clinical stage and pathological grade.

50 ency of lymph node metastasis increased with clinical stage and was similar to that in historical sur

51 ifferences of clinical outcome in respective clinical stages and individual 'stage, size, grade and n

52 can progress over years through a series of clinical stages and lead to irreversible neurological or

53 grative topological measures correlated with clinical stages and prognosis, which was further validat

54 could be used as a personalized variable for clinical staging and aphasia treatment planning.

55 e findings may potentially contribute to the clinical staging and monitoring of Stargardt disease.

56 for glucose, a feature that is exploited in clinical staging and response monitoring by using (18)F-

57 m prostate-specific antigen, tumor grade and clinical stage) and by treatment type (radical prostatec

58 or relapsed HL (duration of first remission, clinical stage, and anemia at relapse), patients with tw

59 Demographics, distribution of clinical stage, and cause of death did not differ betwee

60 correlated with larger tumor size, advanced clinical stage, and low survival rate in OSCC patients.

61 for adjuvant hormonal treatment, HR status, clinical stage, and nuclear grade, patients who achieved

62 corresponding antigens, functional pathways, clinical stage, and outcome were examined.

63 lonic disease at presentation, tumor height, clinical stage, and pelvic radiation.

64 ng centre, largest radiological tumour size, clinical stage, and prespecified chemotherapy regimen.

65 r, human epidermal growth factor receptor 2, clinical stage, and regional lymph node metastasis statu

66 with poorer tumor differentiation, advanced clinical stage, and shorter patient survival.

67 tatus, histologic subtype, T stage, N stage, clinical stage, and treatment method.

68 m SUV, performance status, T stage, N stage, clinical stage, and treatment type (surgery vs other) we

69 e, race, marital status, educational status, clinical stage, and tumor characteristics, increasing pa

70 The condition was classified into 4 clinical stages: annular anterior capsule thickening wit

71 Later clinical stages are accompanied by impaired central visi

72 ntification and treatment of AD in the early clinical stages as well as before cognitive symptoms eme

73 Starting from a clinical-stage asymmetric disulfide lead, we have identi

74 characteristics including ethnicity, age and clinical stage at diagnosis, age at parity, number of fu

75 destructive v metastatic) were unrelated to clinical stage at initial presentation, treatment histor

76 after neoadjuvant chemotherapy, rather than clinical stage at presentation.

77 o test a method of brief pain assessment and clinical staging based on recognized focal features of c

78 therapy determines prognosis rather than the clinical stage before neoadjuvant chemotherapy, indicati

79 er investigator compiled data about baseline clinical stage, biopsy findings, and serum PSA measureme

80 prognostic models: one with CD4 cell count, clinical stage, bodyweight, age, and sex (CD4 count mode

81 to improve the decision making at the early clinical stage by using innovation and the high-profile

82 Voruciclib, an orally bioavailable clinical stage CDK-selective inhibitor, potently blocks

83 for non-Hodgkin lymphomas are not useful for clinical staging classification of most primary cutaneou

84 e in vivo efficacies notably superior to the clinical stage compound pretomanid (PA-824).

85 This clinical stage compound was shown to bind the minimal ca

86 ing for known survival covariates, including clinical staging criteria, the IHC panel remained an ind

87 equipoise regarding the optimal treatment of clinical stage (CS) I nonseminomatous germ cell testicul

88 PURPOSE Patients with clinical stage (CS) IIA and IIB nonseminomatous germ cel

89 nt chemotherapy on the basis of pretreatment clinical stage (CS), estrogen receptor status (E), grade

90 ating the American Joint Committee on Cancer clinical stage (CS), final pathologic stage (PS), estrog

91 en (</=80 years) diagnosed in 2011-2012 with clinical stage cT1-2, localized prostate cancer, with pr

92 n of CRT to surgical resection, adjusted for clinical stage, demographic information, and CRT regimen

93 staging for breast cancer has a pretreatment clinical stage designation that is determined by clinica

94 strains and are constituents of vaccines in clinical-stage development, these findings will aid in r

95 sms in common, and then assesses the various clinical-stage diabetes drugs for their potential activi

96 ic variability, which can make diagnosis and clinical staging difficult.

97 The clinical-stage drug candidate Q203 interferes with the f

98 The discovery of the clinical stage, dual FAK/ALK inhibitor 27b, including de

99 have delivered inhibitors reaching advanced clinical stages due to several challenges in the discove

100 none of the evaluated risk factors (ie, age, clinical stage, elevated erythrocyte sedimentation rate,

101 us knowledge, and linkage to care) and three clinical stages (eligibility for antiretroviral therapy

102 relation to Parkinson disease diagnoses at 3 clinical stages: established (cases diagnosed before 199

103 iding preclinical support for the use of the clinical stage FAK/PYK2 inhibitors for treatment of MM,

104 ls of p-IRAK-4 levels did not correlate with clinical stage, gender, or age, but attenuated IRAK-1,-4

105 found with estimated dose or type of statin, clinical stage, Gleason score, or with prediagnosis stat

106 t association was found between the baseline clinical stage, Gleason score, serum PSA level, or the p

107 specific antigen [PSA] level, Gleason grade, clinical stage, greatest percentage of cancer in all bio

108 72 women with biopsy-proved cervical cancer (clinical stage > or = IB).

109 , histologic type of the tumor, T stage, and clinical stage had no influence on relapse (P = 0.180, P

110 gence of resistance observed for the current clinical-stage hepatitis C virus (HCV) NS3 protease inhi

111 ong DT patients included younger age, higher clinical stage, higher Gleason score, and higher prostat

112 ggressive disease features, such as advanced clinical stage, higher white blood cell counts, and shor

113 abnormalities included CD4 cell count nadir, clinical staging, history of AIDS-defining events, infec

114 ariate model that included age, pretreatment clinical stage, hormone receptor status, hormone therapy

115 zard ratio [HR] = 2.33, P < .0001), advanced clinical stage (HR = 2.75, P = .0025), poor risk cytogen

116 several management options for patients with clinical stage I (CS1) nonseminomatous germ cell tumors

117 etrospective study including data from 2,483 clinical stage I (CSI) patients, 1,139 CSI nonseminoma a

118 n 1997 and 2002, 502 patients with suspected clinical stage I (T1-2N0M0) NSCLC were prospectively enr

119 y 1999, 636 women (age >/= 70 years) who had clinical stage I (T1N0M0 according to TNM classification

120 A total of 8772 patients with clinical stage I 0.50 to 1.0 mm thin melanoma undergoing

121 The outcome among patients with clinical stage I cancer that is detected on annual scree

122 The 8 participants with clinical stage I cancer who did not receive treatment di

123 Among the 302 participants with clinical stage I cancer who underwent surgical resection

124 ng those who underwent surgical resection of clinical stage I cancer within 1 month.

125 ients with carcinoma in situ and 39,941 with clinical stage I cancer.

126 nd retroperitoneal lymph node dissection for clinical stage I disease in January 2010, which revealed

127 ecific survival rate among participants with clinical stage I lung cancer that was detected on CT scr

128 Of these participants, 412 (85%) had clinical stage I lung cancer, and the estimated 10-year

129 Of 35 patients enrolled, 33 (94%) had clinical stage I NSCLC and two (6%) had clinical stage I

130 ell tolerated in a high-risk population with clinical stage I NSCLC.

131 ts and Methods Adult patients with resected, clinical stage I or II adenocarcinoma of the head of the

132 Results We identified 15,237 patients with clinical stage I or II resected pancreatic head adenocar

133 Of clinical Stage I patients 71.4% (6823/9559) did not unde

134 nce a relapse after adjuvant carboplatin for clinical stage I seminoma can be successfully treated wi

135 gies that may follow inguinal orchiectomy in clinical stage I seminoma.

136 urveillance is a widely accepted strategy in clinical stage I testicular cancer treatment in the comm

137 Patients with clinical stage I testicular germ cell tumors have been m

138 s) with limited-stage small-cell lung cancer clinical stage I to III who received CT or CRT were iden

139 isease in 1 of 20 (5%) patients with initial clinical stage I, 2 of 44 (5%) stage IIA, 8 of 47 (17%)

140 Most (61%) were clinical stage I, with 31% stage II, and 7% stage III.

141 titutions was used to identify patients with clinical stage I-III rectal cancer undergoing surgery (n

142 Patients with clinical stage I-IIIA breast cancer were randomly assign

143 Patients age 15 to 70 years with untreated clinical stage I/II HL were eligible.

144 ment resulted in fewer early progressions in clinical stage I/II HL, although early outcome was excel

145 ment is standard treatment for patients with clinical stage I/II Hodgkin lymphoma (HL).

146 potentially resectable tumors (pretreatment clinical Stage I: T1N0M0 and T2N0M0).

147 atients were identified: 8,073 patients with clinical stage IA and 8,525 patients with clinical stage

148 B use was reported in 13.3% of patients with clinical stage IA melanoma and was more likely in patien

149 with clinical stage IB/II melanomas, but not clinical stage IA melanoma.

150 vival rates of patients with first, primary, clinical stage IA nonsmall cell lung cancer from a large

151 l study of 787 patients with newly diagnosed clinical stage IB or II melanoma, we estimated odds rati

152 PATIENTS AND METHODS Patients with clinical stage IB-IIIA NSCLC (excluding superior sulcus

153 Patients with clinical stage IB/II melanoma were less likely to underg

154 For clinical stage IB/II melanoma, SLNB use was reported in

155 th clinical stage IA and 8,525 patients with clinical stage IB/II melanoma.

156 l lymph node biopsy (SLNB) for patients with clinical stage IB/II melanomas, but not clinical stage I

157 Patients operated on for clinical stage II and III rectal cancer were selected fr

158 had clinical stage I NSCLC and two (6%) had clinical stage II NSCLC.

159 2 trial of neoadjuvant therapy for high-risk clinical stage II or III breast cancer, evaluated multip

160 Ninety-eight consecutive patients with clinical stage II or III ER+/HER2- breast cancer were in

161 Patients with clinical stage II or III rectal cancer who were undergoi

162 A total of 486 patients with clinical stage II or III rectal cancer within 12 cm of t

163 Eligible patients had clinical stage II-III (> or = T2 and/or > or = N1) newly

164 ts in the independent validation cohort (99% clinical stage II-III) who were predicted to be treatmen

165 Of 607 patients presenting with clinical stage II/III disease, chemotherapy downstaged 3

166 erapy achieves low local recurrence rates in clinical stages II to III rectal cancer, it delays admin

167 For selected patients with clinical stages II to III rectal cancer, neoadjuvant che

168 the role of FDG PET/CT in initial staging of clinical stage IIA and IIB and primary operable stage II

169 From 1989 to 1997, clinical stage IIa, IIb, IIc, and III NSGCT was seen in

170 l surgery improved survival in patients with clinical stage IIB/IIIA NSCLC.

171 uidelines consider (18)F-FDG PET/CT for only clinical stage III breast cancer patients.

172 uld be considered for those who present with clinical stage III disease or have histologically positi

173 receiving CRT decreased with increasing age, clinical stage III disease, female sex, and the presence

174 gressive (biopsy Gleason score >/= 7, and/or clinical stage III or greater, and/or fatal).

175 G PET/CT (or (18)F-FDG PET) in patients with clinical stage III or II breast cancer.

176 variate analysis, an age less than 50 years, clinical stage III, grade 3, estrogen receptor (ER)-nega

177 re with risk factors (RFs) of early relapse, clinical stage III/IV, and anemia identified patients wi

178 Overall, (18)F-FDG PET/CT changed the clinical stage in 61 patients (52%).

179 ditional prognostic information over TLG and clinical staging in patients with advanced T-stage OPSCC

180 er MTV and TGA add prognostic information to clinical staging in patients with oral and oropharyngeal

181 The use of clinical staging in the fatal neurodegenerative disease

182 ck of a suitable animal model, mimicking all clinical stages, in particular the healing process, rema

183 id sequences from 137 antibodies in advanced clinical stages, including 48 approved for therapeutic u

184 ms certain that some of them will advance to clinical stage investigations.

185 ted by FDG-PET in cervical cancer relates to clinical stage, is comparable to historical data, and st

186 Furthermore, advanced clinical stage, lack of p16 expression, and MYC and CCND

187 n and their contribution to pathological and clinical stages leading to vision loss in diabetic retin

188 o detect MGA expression, especially in early clinical stage, low grade and lymph node metastasis-nega

189 ate cancer, as assessed by low-risk disease (clinical stage </=T2a, biopsy Gleason score </=6, and pr

190 l in prostate adenocarcinoma correlated with clinical stage, lymph node status, and Gleason score.

191 , preclinical, and clinical studies of these clinical-stage MDM2 inhibitors.

192 Published data relevant to clinical staging, monitoring of tumor response, and loco

193 NFL concentration is increased by the early clinical stage of AD and is associated with cognitive de

194 dysfunction and SR Ca(2+) leak depend on the clinical stage of AF or specific animal model studied.

195 eurogranin is increased already at the early clinical stage of Alzheimer's disease and predicts cogni

196 Evolution of visual acuity and clinical stage of BVMD correlated to OCT measurement par

197 ed tomography scan, the tumor was assigned a clinical stage of cT2N0.

198 ple with an increased risk of developing the clinical stage of glaucoma.

199 e of HCC patients, and which correlated with clinical stage of HCC, were NAA, dimethylglycine, 1-meth

200 ly correlated with lymph node metastasis and clinical stage of NPC.

201 een the loss of Hcrt and MCH neurons and the clinical stage of PD, in contrast to the lack of a relat

202 eurons are significantly correlated with the clinical stage of PD, not disease duration, whereas the

203 ce of subclinical motor dysfunction at a pre-clinical stage of SCA6.

204 ation carriers, in the later preclinical and clinical stages of ADAD, mutation-carrying children were

205 fferent AD biomarkers in the preclinical and clinical stages of autosomal dominant AD.

206 tween the expression levels of EcSOD and the clinical stages of breast cancer.

207 nt signaling events in patients at different clinical stages of chronic chagasic heart disease.

208 effector and regulatory responses can define clinical stages of chronic hepatitis B (CHB).

209 R, and the findings were correlated with the clinical stages of disease and histopathologies.

210 linguistic impairment through the successive clinical stages of disease.

211 s that may be applied to patients in various clinical stages of disease.

212 pies presents a substantial challenge in the clinical stages of drug development for oncology.

213 slation of knowledge between preclinical and clinical stages of drug development.

214 to identify human Tregs and the diversity of clinical stages of HIV infection.

215 these changes are present from the earliest clinical stages of multiple sclerosis; (ii) they occur i

216 ly associated with pathological and advanced clinical stages of NPC.

217 the relationships between age, the advanced clinical stages of Parkinson's disease and neuropatholog

218 Our results suggest that at clinical stages of prion infection, dysregulation of res

219 of 12-HETER1 positively correlates with the clinical stages of prostate cancers and Gleason scores.

220 rbation, is affected at the pre-clinical and clinical stages of spinocerebellar ataxia type 6 (SCA6),

221 Clinical staging of cervical lymph nodes from patients w

222 entified as a good tumor-specific marker for clinical staging of cervical sentinel lymph nodes in hea

223 ales and 72 % were in the Stage 3 of the WHO Clinical Staging of HIV infection.

224 Clinical staging of MacTel was based on best-corrected v

225 g has allowed for more accurate preoperative clinical staging of renal tumors, and the necessity of c

226 emodeling that may find applicability in the clinical staging of TB patients.

227 epithelial neoplasia lesions correlated with clinical staging of the tumor (rho = -0.4, P = 0.0474) w

228 ter neoadjuvant chemotherapy than presenting clinical stage or final pathologic stage.

229 rimary samples studied irrespective of their clinical stage or prognostic marker phenotype.

230 sion levels of KISS1 in PCas correlated with clinical stage (P < 0.01) and with KISS1R expression (P

231 gnosis (P = .01), tumor stage (P = .01), and clinical stage (P = .001) were found to be significant p

232 002), and American Joint Committee on Cancer clinical stage (P = .02).

233 th solid histology (P = 0.008), and advanced clinical stage (P = 0.009).

234 survival rates when comparing the presenting clinical stage (P = NS).

235 omes derived from multivariate analysis were clinical stage (P<0.0001), location of the tumor (P=0.02

236 (P= 0.98), histologic subtype (P= 0.17), or clinical stage (P= 0.097).

237 NMRP expression were evident at the earliest clinical stages (p < 0.05), which progressed significant

238 m had the greatest prognostic impact in late clinical stages (P = 0.006).

239 expression was significantly associated with clinical stage, pathologic tumor status, distant metasta

240 y, which in general is much lower than other clinical stage PI3K inhibitors.

241 neoadjuvant chemotherapy using pretreatment clinical stage, posttreatment pathologic stage, estrogen

242 score, prostate-specific antigen level, and clinical stage--predicts progression-free survival among

243 These results should improve MRI-guided clinical staging, presurgical planning, and intraoperati

244 1 scans: range 3-8 per patient) at different clinical stages (presymptomatic, mild cognitive impairme

245 rmed before surgery or biopsy as part of the clinical staging procedure.

246 nostic factors including high Gleason score, clinical stage, prostate-specific antigen (PSA) and exte

247 a correlation between staining intensity and clinical stage; PTEN expression was decreased in the col

248 We stratified randomisation by clinical stage, receptor status, and country and used pe

249 Clinical stage, risk assessment, and treatment plan were

250 DM was compared controlling for patient age, clinical stage, serum prostate-specific antigen level, b

251 In a multivariate analysis, advanced clinical stage, severe histologic damage, and high REG3a

252 ariable analysis adjusting for extent of RT, clinical stage, sex, and use of chemotherapy confirmed t

253 ed hazard ratio 0.21, 95% CI 0.17-0.27), WHO clinical stage (stages III-IV vs I-II; 3.45, 2.43-4.90),

254 ed system based on World Health Organization clinical staging, standardized first-line ART regimens,

255 ed, with the same number of patients in each clinical stage subgroup (12 stage I patients, 32 stage I

256 reviewed, and the DMR was recorded for each clinical stage subgroup (stages I-III).

257 seventh edition tumor-node-metastasis (TNM) clinical staging system for OAL and followed every 6 to

258 sus-host disease (GvHD) is based on either a clinical staging system or histological or endoscopic fi

259 he American Joint Committee on Cancer (AJCC) clinical staging system, T3 and T2 lesions portended a h

260 40 to 80 years with a GS between 2 and 6 and clinical stage T1 or T2 prostate cancer enrolled between

261 CI, 0.94-2.03), as did current smokers with clinical stage T1 through T3 (HR, 1.41; 95% CI, 0.80-2.4

262 CI], 1.11-2.32), as did current smokers with clinical stage T1 through T3 (HR, 1.80; 95% CI, 1.04-3.1

263 A total of 1,650 patients with clinical stage T1 to T3 prostate cancer were treated wit

264 did not receive definitive local therapy for clinical stage T1-T2 prostate cancer.

265 Early GBC included clinical stage T1/T2.

266 cohort study of Medicare beneficiaries with clinical stage T1a kidney cancer treated with partial or

267 However, for clinical stage T1b tumors this provides a unique challen

268 performed with or without hilar clamping for clinical stage T1b tumors.

269 with esophageal adenocarcinoma histology and clinical stage T1bN1-N3 or T2-T4aN-/+M0 were divided int

270 R imaging may help to stratify patients with clinical stage T1c disease for appropriate clinical mana

271 e, 58 years; age range, 40-76 years) who had clinical stage T1c prostate cancer, had not been treated

272 Clinical stage T1c prostate cancers are heterogeneous in

273 t, 2 cm or greater in diameter by palpation, clinical stage T1c-3, cN0, cN1, or cN2a, without metasta

274 ed from 2004 to 2007 with low-risk prostate (clinical stage T1c/T2a; Gleason score, </=6; and prostat

275 Patients with clinical stages T1c-T3b prostate cancer were treated wit

276 a were for very-low-risk cancers, defined by clinical stage (T1c), prostate-specific antigen density

277 ery-low-risk (subset of the low-risk group) (clinical stage, T1c; Gleason score, </=6; prostate-speci

278 Entry was limited to patients with clinical stage T1N0 or T2N0 NSCLC (< 4 cm) and pulmonary

279 reated low-volume low-grade prostate cancer (clinical stage T2a or lower; Gleason score, 3+3; index t

280 Gleason score >7, locally advanced disease (clinical stage T3/T4), and extensive disease on prostate

281 Eligible patients had clinical-stage T3 rectal adenocarcinoma within 12 cm of

282 otential advantage of extended resection for clinical stage T4b gastric adenocarcinoma with good long

283 th higher odds of Parkinson disease at all 3 clinical stages: the odds ratios comparing long nappers

284 In addition to clinical stage, these parameters could represent the min

285 astasis suppressive activity of entolimod, a clinical stage TLR5 agonist that activates NF-kappaB-, A

286 onella flagellin structurally analogous to a clinical stage TLR5 agonist, entolimod.

287 , and we classified patients by tumour site, clinical stage (TNM system), and post-surgical stage (In

288 SA) concentration, biopsy Gleason grade, and clinical stage to classify patients as low, intermediate

289 ected included demographics, diagnosis date, clinical stage, treatment, and outcome 1,082 patients me

290 th tGIV and pYGIV showed no correlation with clinical stage, tumor size, pathologic type, lymph node

291 (24%) had germline BRCA1 or BRCA2 mutations; clinical stage was I (13%), IIA (36%), IIB (36%), and II

292 The distribution of clinical stages was: I, 2.2% II, 3.4% III, 13% IVa, 27%

293 Clinical staging was more helpful in predicting outcome

294 Clinical staging was the best predictive method and no i

295 To advance the therapy to clinical stage, we generated new stable vectors in AAV8

296 Lower CD4, older age, and advanced clinical stage were associated with higher sCD14.

297 s in the cascade, the transitions across the clinical stages were fast.

298 The CD4 + T cell count and WHO clinical staging were determined.

299 utation status, CD38 or ZAP-70 cytogenetics, clinical stage) were significantly associated with time

300 ups (PSA concentration, Gleason grading, and clinical stage) were then used to sub-stratify within ea

301 e primarily associated with tumor burden and clinical stage, whereas tumor TLG is the best predictor

302 ul as it provides an opportunity to assess a clinical stage which in most subjects represents prodrom